A Phase2A, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of a Single-Dose Intravenous Administration of MEDI-528, A Humanized Anti-Interleukin-9 Monoclonal Antibody, on Allergen-Induced Interleukin-9 Levels in Bronchoalveolar Lavage Fluid in Adults With Atopic Asthma.

Trial Profile

A Phase2A, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of a Single-Dose Intravenous Administration of MEDI-528, A Humanized Anti-Interleukin-9 Monoclonal Antibody, on Allergen-Induced Interleukin-9 Levels in Bronchoalveolar Lavage Fluid in Adults With Atopic Asthma.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 05 May 2014

At a glance

  • Drugs Enokizumab (Primary)
  • Indications Allergic asthma; Asthma
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors MedImmune
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 18 Feb 2010 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
    • 25 Aug 2008 Status changed from recruiting to suspended (clinical hold), as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top